Chapel Hill, NC 27516
PURE ONE 300 mg DHA (API) [Coming in July]
I Love Algae Oil. Love is the only way. When you know how to Love, it makes all the difference. Keeping a daily dose of omega-3 is also clearly needed. Simple as that! There are too many reasons to take omega-3. There is only one way. Daily. This has been proven with algae oil omega-3s also. You take medications every day. The reasons are known by your doctor. Daily intake of at least 600 mg/day of total long-chain omega-3 fatty acids is needed in the same way. We can show you how and the repeatedly proven results. Dr Doughman has also submitted publication to prove 1200 mg DHA is even better for you, in review [IJDDC], based on the same evidence-based research that was recently published by Harvard. - Dr Doughman
AWESOME NEW PARTNER PRODUCTS!
"Deva has built into thier product 9 years of excellence in innovations, combined with Source-Omega's 5 years of algae oil research and results on OMEGA-3 DHA THERAPY [6 SOFTGELS FOR 1200 MG DHA]. We independently certify each product through our qualtiy seal. That means we can independently validate each product and its claims. This means that you can rely upon Source-Omega's certified product offerings for your optimized health. We are standardizing intake levels and doses for real and measureable results using algae oil omega-3s, according to documented results on file, the evidence-based literature and our peer-reviewed publications surveying 16 clinical trials."
"DEVA OMEGA-3 DHA gives pure oil and full omega-3 DHA benefits, is vegan, soy free, gluten and wheat free, uses non-GMO modified corn starch, and all the same ingredients as Pure One. DEVA came before Pure One. It works EXACTLY THE SAME," - says Dr. Scott Doughman, PhD
Scott Doughman, PhD
Chief Scientific Officer and CEO Source-Omega, LLC.
Lipidologist Developer of Pure One™ and CereNate™ [formula series VG0046] [Established 2007]
DEVA, PURE ONE and CERENATE are certified NON-GMO 
by Dr Doughman, Jan 10, 2012
GOED and Frost & Sullivan trade reports show 80% of all fish harvest in the world is from only anchovy/sardine, a staple for land-lovers and under the sea. Also, in 2008, only about 12% - 25% of all fish oil was used for food/supplement omega-3 ingredients. Total omega-3 oil nutritional demand in 2012 is projected to account for about 50% - 60% of a typical capped world oil production capacity. Further trending suggests increased prices for fish oil as omega-3 demand is expected to outpace historic caps before 2020.
But food is only part of this story. Another point is that concentrates and ethyl esters require 10kg fish oil for 1kg concentrate, i.e. one order of magnitude. Yet pharmaceutical preparations are commanding 20kg for every 1kg of product during the refinement, plus the R&D development cycles are rapidly expanding new drug projects. Thus, the science and technology pressures help drive the value of omega-3s into non-commodity high-priced products with lower supply efficiency.
Algae oil is the only mass-produced alternative. This sounds like the bell that tolls for the gathering of the faithful.
"In direct studies, algae oil cardio-protective effects from DHA was due to lowering plasma triglycerides and levels of oxidative stress. Also because statins may lower all cholesterol, both good and bad forms, DHA may help raise the good HDL levels to improve your cholesterol." -Dr Doughman, PhD
Dr Doughman, PhD Suggested Recommendation:
4 Concentrated Omega-3 Capsules Daily
(Four Pure One Capsules Give 1200mg DHA + 40 mg EPA)
|Buy 5 get 1 FREE||ABOUT DR DOUGHMAN, PHD|
Omega-3 fatty acids have anti-arrhythmic effects, including
See the support article for more information
Pure One™ is the first scientifically Optimized Omega 3 available. It has the dose of DHA and EPA at a ratio that most closely matches your body's needs.
In the 1970's researchers noted that Eskimo populations consumed extremely high levels of fat from fish and blubber, but this contradicted hypotheses of coronary heart disease at the time because the indigenous populations had no signs of cardiovascular disease. High levels of EPA/DHA are thought to be the protective complement. Recently, DART and GISSIP clinical studies of fish oil supplementation revealed 15-45% reduction in mortality in 'at risk' patients for coronary heart disease. Reductions in sudden death were particularly significant.
One small fish oil supplementation study in Norway did not show significant improvements, probably because of habitual incorporation of cold water fish as a regular part of the diet. The latter result can be explained by assuming that omega-3 status was optimum to begin with, suggesting that with full EPA/DHA essentiality in the background this meant coronary heart diseases in Norway were likely due to additional factors such as obesity or genetic factors that played dominant roles in participating subjects. However, most of the risks of coronary heart disease globally are associated with diet. A high incidence of diet induced coronary heart disease occurs in many countries, including India.
The benefits of omega-3s were originally thought to be due to their antithrombotic effects, but recent evidence has indicated that the predominant effect may be antiarrhythmic. Omega-3 supplementation decreased heart rate variability in patients after myocardial infarction, which correlated with a lower risk of mortality and malignant arrhythmia. In fact, direct addition of EPA/DHA into media with cultured cardiomyocytes prevents or terminates pharmacologically induced or electrically clamped arrhythmias. The modulation of plasma membrane permeability and the stabilization of ion channel functions are suggested to be acute protective properties of EPA/DHA on heart muscle cells.
Omega 3 fatty acids may also influence the atherosclerotic process. Again, in patients with coronary heart disease EPA/DHA supplementation versus placebo for two years resulted in modest improvements in atherosclerosis as assessed by angiography. An important recent study of patients awaiting carotid artery surgery randomized cohorts to fish oil capsules, sunflower oil capsules, or controls up until surgery and then assessed morphology of the plaque. Omega 3 fatty acids incorporated into atherosclerotic plaques in the fish oil group, and these plaques were more likely to have reduced mass with less inflammatory infiltrate and increases in thickness of fibrous caps from protective responses. These features imply a plaque that is less vulnerable to rupture and indicates EPA/DHA may help to establish plaque stability. Additional improvements in overall endothelial function and decreases in pro-inflammatory signals have also been noted. The fundamental cellular processes activated or suppressed by omega-3 supplementation and their potential impact on coronary heart disease are active areas of research.